Medtronic’s Israeli Unit Hit with Massive $190M Tax Seizure Over IP Transfer Dispute

The court's decision was based on the finding that Ventor had transferred its functions, assets, and risks (FAR) to its parent company, Medtronic Inc., in a manner that constituted a taxable sale. The ITA argued that the intercompany agreements between Ventor and Medtronic, which included research and development services and licensing arrangements, reflected a transfer of FAR, thereby triggering tax liabilities.

Medtronic Ventor has petitioned Israel's Supreme Court for a stay of execution, contending that its assets are insufficient to cover the tax debt. The company claims that its assets total less than 5% of the tax liability, approximately NIS 28 million, and seeks to delay enforcement actions until the appeal process is concluded. Until recently, no liens had been imposed, and both parties were engaged in negotiations aimed at reaching a settlement.

The origins of this dispute trace back to Ventor's establishment in 2004, when it developed a minimally invasive aortic valve implant that could be inserted through the chest wall, avoiding open-heart surgery. In 2009, Medtronic acquired Ventor for $325 million, and the company continued to operate in Israel as Medtronic's research and development center. However, in April 2012, Medtronic decided to shut down Ventor's Israeli development activities, though the company continued to earn royalties from its intellectual property.

The Israeli Tax Authority's actions have raised concerns about the treatment of intellectual property transfers in international acquisitions. The case underscores the complexities of cross-border tax regulations and the potential financial implications for multinational corporations operating in Israel. As the legal proceedings continue, the outcome may have broader implications for how similar transactions are assessed and taxed in the future.